Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy

Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining ...
Las Vegas Sun

Rare Earths Americas Identifies Large Rare Earth-Niobium Alkaline-Carbonatite System; Discovery Model Strengthens as 15,000m Drill Program Gets Underway at Homer

Rare Earths Americas, Inc. ("REA" or the "Company"), today announced exploration results that strengthen the Company's geological discovery model at its 100%-owned Homer-A project in Brazil's Goiás ...
The Caledonian-Record

Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial

Can-Fite has reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients achieved ...

AI, Clinical Data, and Regulatory Catalysts have Wall Street Watching These Biotechs

Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the ...
Healio

Remibrutinib helps adults with chronic inducible urticaria achieve symptom control

More adults with chronic inducible urticaria receiving remibrutinib vs. placebo achieved complete symptom control at week 12, ...
The Manila Times

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months ...
A to Z Sports on MSN

Phil Mafah's Player Profile: The former seventh-rounder with an advantage to lock down Dallas Cowboys' No. 2 running back spot

The Dallas Cowboys running back competition is wide open behind Javonte Williams. So ruling out Phil Mafah's power is a ...
The Manila Times

CHMP recommendation advances Johnson & Johnson’s TECVAYLI® (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall ...

Absci Corporation: Absci Announces Positive Interim Phase 1 Data from the HEADLINE Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts ...
The News-Gazette

Champaign gears up for second phase of Neil Street Plaza

A map depicting the project area for Phase 2 of downtown Champaign’s Neil Street plaza. Looking south at parking in the north end of the Neil Street plaza in downtown Champaign on Wednesday, Dec. 17, ...